Community Healthcare Trust Inc (CHCT) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-08

Key Insights

Director Van Horn R. Lawrence acquired 6,222 shares of CHCT common stock on 05/07/2026 at $0 price, indicating a grant or award rather than an open market purchase, bringing total beneficial ownership to 94,724 shares.
The zero-dollar transaction price suggests this acquisition was compensation-related (likely restricted stock grant or equity incentive plan award) rather than a discretionary insider buy, which is less indicative of confidence in the stock's valuation.
As a Director holding over 94,000 shares post-transaction, Lawrence maintains meaningful skin in the game, though the nature of the acquisition (grant vs. purchase) provides limited insight into insider sentiment regarding future stock performance.

Want the newest filings?

This analysis covers the filing from 2026-05-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-05-08

Director Alan Gardner acquired 6,222 shares of CHCT common stock on 05/07/2026 at $0 per share, indicating this was likely a stock grant, dividend reinvestment, or compensation-related transaction rather than open market purchase.
Following the transaction, Gardner's beneficial ownership increased to 96,860 shares held directly, suggesting a meaningful stake in the company and alignment with shareholder interests.
The transaction was filed by attorney-in-fact Nathanael P. Kibler on 05/08/2026, one day after the transaction date, which is compliant with SEC filing requirements.
This appears to be a routine director compensation or equity grant rather than a discretionary market purchase, limiting the signal value regarding insider confidence in the stock's valuation.

Filed: 2026-05-08

Director Robert Z. Hensley acquired 6,222 shares of CHCT common stock on 05/07/2026 at $0 price, indicating a stock grant or equity compensation rather than open market purchase.
Following this transaction, Hensley's direct beneficial ownership increased to 89,666 shares, demonstrating significant insider stake alignment with shareholder interests.
The filing shows insider equity compensation activity typical for board members, with no indication of concern-raising selling patterns or insider disposition.

Filed: 2026-05-08

Director Cathrine Cotman acquired 6,222 shares of CHCT common stock on 05/07/2026 at $0 price, indicating a grant or award rather than open market purchase, bringing total beneficial ownership to 43,857 shares.
The transaction was executed through an attorney-in-fact (Nathanael P. Kibler), suggesting this was part of a formal compensation or equity incentive plan rather than a discretionary insider trade.
No derivative securities activity is reported, indicating no options or warrants were exercised, which limits visibility into potential larger insider accumulation strategies.

Filed: 2026-05-08

Director Claire M. Gulmi acquired 6,222 shares of CHCT common stock on 05/07/2026 at $0 price, indicating a grant or equity compensation rather than open market purchase, with total beneficial ownership reaching 63,862 shares.
The transaction was executed at zero dollar consideration, suggesting this represents restricted stock awards, performance shares, or other equity incentive compensation typical for board members rather than voluntary insider buying.
The filing shows routine director compensation activity with no indication of material insider selling pressure, which is neutral to slightly positive from a governance perspective.

Filed: 2026-01-20

The CEO and President, David H. Dupuy, has received a significant amount of restricted stock as part of his 2026 compensation, indicating alignment with shareholder interests.
Dupuy acquired 29,941 shares of common stock at $16.70 per share, increasing his direct beneficial ownership to 534,245 shares.
The restricted stock award with a 5-year restriction period suggests long-term commitment and confidence in the company's future performance.

Filed: 2026-01-20

William G. Monroe IV, the Executive Vice President and CFO, has been awarded 29,605 shares of restricted stock as part of his 2026 compensation package. This indicates management's confidence in the company's future performance.
The restricted stock has an 8-year vesting period, which aligns the executive's interests with long-term shareholder value creation.
The purchase price of $16.70 per share is based on the average stock price in the 10 trading days preceding the transaction, suggesting the company's stock is trading at a fair value.

Filed: 2026-01-20

The reporting person, Leigh Ann Stach, who is the Executive Vice President and Chief Accounting Officer of Community Healthcare Trust Inc (CHCT), acquired 17,889 shares of the company's common stock as part of a compensation agreement to take 50% of her 2026 salary in restricted stock.
Stach also had 4,643 shares withheld for tax purposes, indicating she is still bullish on the company and retaining a significant portion of the awarded shares.
The acquisition price of $16.70 per share suggests the company's stock is considered undervalued by the reporting person, who is an insider and key executive.

Other reports for Community Healthcare Trust Inc

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.